Q-Line Biotech Ltd Q2 FY27 results (latest), Jul–Sep 2026 →See revenue, profit and what management said. You are viewing Q4 FY26.
QB

Q-Line Biotech Ltd

Q4 FY26Healthcare Equipment & Supplies

Q-Line Biotech Q4 FY26 earnings call: Revenue & Margins

Q4 FY26 earnings call: what management said on revenue, margins and capex.

What the Q4 FY26 call signalled

4 of 4 strong

RevenueGood growth
MarginMargins up
CapexCapex planned
Order bookOrder book rising
Price₹700
Market cap₹1.6K Cr
P/E28.8

The short version

Targeting revenue growth of approximately 30% to 35% in FY27 driven by increased utilization of manufacturing facilities and commercialization of new products (Page 6, 5). Q-Line Biotech targets revenue growth of approximately 30% to 35% for FY27, driven by increased utilization of manufacturing facilities, new product commercialization, export expansion, and disciplined cost management.

From Q-Line Biotech Ltd's Q4 FY26 earnings-call transcript · updated 23 Sept 2026.

Revenue & Sales Performance

Good growth
  • Targeting revenue growth of approximately 30% to 35% in FY27 driven by increased utilization of manufacturing facilities and commercialization of new products (Page 6, 5).
  • Reagents revenue expected to grow by 30% to 35% in the current year, continuing as the primary growth driver due to recurring demand and strong margins (Page 7, 6; Page 5, 5).
  • Installed base of instruments growing with plans to add 2,000+ instruments in the current year, supporting recurring reagent sales (Page 10, 9).
  • Unit 4 manufacturing facility capacity expected to scale 3x to 4x current revenue in reagent and CDMO business by FY30 (Page 15, 14).

2 more points from Q-Line Biotech Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Q-Line Biotech Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned
  • No major capex expected in the next 2-3 years; current CWIP (~INR 15 crore) mostly for a new plant planned to be used as warehouse initially.
  • Additional capex possible if CDMO business for large equipment grows, requiring expanded space.
  • Unit 4 manufacturing capacity allows 3-4x current revenue growth without extra capex, supporting reagent and CDMO expansion.

2 more points from Q-Line Biotech Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Healthcare Equipment & Supplies

Ranked on what management guided this quarter

Guidance-ranked
1OSEL Devices
Rev 1Mar 3
Rev 1Mar 3
3
Rev 2Mar 3
4
Rev 2Mar 3
5
Rev 2Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Q-Line Biotech Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Order book rising
  • Q-Line Biotech has an installed base of approximately 16,000 to 17,000 diagnostic instruments to date.
  • The company plans to add around 2,000 new instruments in the current financial year.
  • Installed base increased by 2,500 instruments in the last two years.
  • Annual instrument placements average 1,200 to 1,300 units, with expected growth to over 2,000 units next year.

2 more points from Q-Line Biotech Ltd's call on order book

Create a free account to keep reading this call

What Q-Line Biotech's management said in earlier quarters

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Q-Line Biotech Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Q-Line Biotech Ltd Q4 FY26 results?

Targeting revenue growth of approximately 30% to 35% in FY27 driven by increased utilization of manufacturing facilities and commercialization of new products (Page 6, 5). Q-Line Biotech targets revenue growth of approximately 30% to 35% for FY27, driven by increased utilization of manufacturing facilities, new product commercialization, export expansion, and disciplined cost management.

What is Q-Line Biotech Ltd share price analysis?

Q-Line Biotech Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 28.8 with a market cap of ₹1,626 Cr. Investors should review the full earnings analysis for detailed insights.

Is Q-Line Biotech Ltd planning capital expenditure?

No major capex expected in the next 2-3 years; current CWIP (~INR 15 crore) mostly for a new plant planned to be used as warehouse initially.

Keep Q-Line Biotech Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.